Integra offers $1B+ bid for J&J’s neurosurgery business

money2
Integra markets surgical instruments and devices across a range of specialties, including wound care, reconstructive surgery and neurosurgery.

Integra LifeSciences has made a binding offer to acquire Johnson & Johnson’s Codman Neurosurgery business for about $1.05 billion in cash.

Codman, which reeled in about $370 million in revenue last year, is part of J&J’s DePuy Synthes group. If J&J accepts the bid, Integra will boost its neurosurgical offerings, getting its hands on surgical devices used to treat brain tumors, hydrocephalus (or the buildup of fluid in the brain) and other neurological disorders.

Codman’s "innovative portfolio and global reach will enable us to enhance our position in the neurosurgery market, while also building a global infrastructure that will benefit Integra as a whole,” said Integra CEO Peter Arduini in a statement. “We look forward to welcoming the more than 600 Codman Neurosurgery employees to the Integra team."

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Integra’s neurosurgery stable includes flow-regulating valves to control the flow of cerebrospinal fluid and a dural sealant system. It has devices for tissue ablation, dural repair and cranial stabilization in its pipeline, according to the statement.

If all goes to plan, the deal should close in two steps, with the first—closure in about 24 principal countries—coming in the fourth quarter.

In 2015, the company snatched up TEI for $312 million to expand its reach in wound care and reconstructive surgery. It also markets surgical instruments and devices across a range of specialties, including pain care and burn surgery.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.